The web link for registration for the 10TH INTERNATIONAL PEDIATRIC RENAL TUMOUR BIOLOGY CONFERENCE is now live.
More details to come soon regarding the agenda.
Feel free to circulate this link to colleagues who are not part of the renal committee but may be interested in the conference.
There is a discounted rate for students to attend if you have trainees who may be interested in the meeting.
Conrad Fernandez MD, FRCPC
Chair, Renal Tumors Committee
The agenda can be found at https://n2canada.ca/wp-content/uploads/2020/01/AGENDA-V5.0.pdf
DIGITAL ATTENDANCE COST
N2 is live streamlining their N2 annual meeting! If you are unable to attend but would like to view the 2-day meeting digitally there is now an option to do so.
- Member registration is $35.00 plus HST
- Non-Member registration is $70.00 plus HST
- Member registration is $75.00 plus HST
- Non-Member registration is $800.00 plus HST (Non-member conference registration fee will be applied to the cost of membership taken out before the end of the conference).
C17 Research Network Update: free download of COMPASSION IN PEDIATRIC HEALTHCARE: A SCOPING REVIEW by C17 grant recipient Shane Sinclair
The final version of the C17/CCC-funded research article by Dr. Shane Sinclair entitled Compassion in pediatric healthcare: a scoping review is now available online, containing full bibliographic details. To help the author access and share this work, Elsevier has created a Share Link – a personalized URL providing 50 days’ free access to their article. Anyone clicking on this link before February 21, 2020 will be taken directly to the final version of the article on ScienceDirect, which they are welcome to read or download. No sign up, registration or fees are required.
|Shane’s personalized Share Link:|
Click on the icons below to share with your network:
This study was conducted with support from C17 and funded by the Ewing’s Cancer Foundation of Canada and Childhood Cancer Canada Foundation, Dr. Sinclair’s Cancer Care Research Professorship and a Bridge Funding Grant from the Faculty of Nursing, University of Calgary.
As February approaches please help spread awareness of the global impact of childhood cancer, as marked on February 15th by International Childhood Cancer Day (ICCD).
Post regularly to social media with graphics and topics that address childhood cancer.
- Use the tag #ICCD2020
- Share posts from www.internationalchildhoodcancerday.org/
- Share posts from Canadian advocacy groups such as Ac2orn
- Share posts from the C17 Council
- The 8th ACCELERATE Pediatric Cancer Conference is on Feb 8 – follow and share news from #ACCELERATEplatform
- A graphics toolkit will be released soon. Post ICCD awareness images at your workplace and in your neighborhood.
“International Childhood Cancer Day is a global collaborative campaign to raise awareness about childhood cancer, and to express support for children and adolescents with cancer, the survivors and their families. The day promotes increased appreciation and deeper understanding of issues and challenges relevant to childhood cancer and impacting on children/adolescents with cancer, the survivors, their families and the society as a whole. It also spotlights the need for more equitable and better access to treatment and care for all children with cancer, everywhere. “
For more information see http://www.internationalchildhoodcancerday.org/About.html
Crush Cancer @ Both Ends of the Leash! Call for abstracts for the Paws For a Cure (PFAC) Research Symposium (June 22-24, Merck Research Labs, Boston). Abstracts due Feb 24th.
We are pleased to announce a Call for Abstracts for the upcoming 2nd Paws For a Cure (PFAC) Research Symposium(June 22-24, 2020 at Merck Research Labs, Boston). This unique meeting, co-hosted by the Canines-N-Kids Foundation and Merck, and will once again bring together more than 200 world class cancer researchers, funders, industry representatives and others to present the state-of-the-art in comparative cancer research, and to discuss challenges and progress in accelerating innovative cancer drug development using comparative approaches specifically relevant to shared pediatric and canine cancers .
Dr. Peter Adamson, Chair of the Children’s Oncology Group and Chair in Pediatrics at The Children’s Hospital of Philadelphia (CHOP) will Keynote this year’s Symposium, and the planned speaker and participant line-up will be top-notch. Building on the first meeting of its kind in November 2018, PFAC 2020 will be a high-level forum in which to showcase emerging, innovative scientific research in comparative oncology, genomics, immunology, imaging and more.
In the Invitation below, you will find links to the meeting site, as well as to additional specifics about the planned PFAC Scientific Poster Exhibition & Young Investigator Competition.
Please share with colleagues who may take an interest in making a submission and/or attending in June. Please note the deadline for Abstract submissions is February 24th.
If you have any questions, please, don’t hesitate to reach out.
Let’s Crush Cancer @ Both Ends of the Leash!
With kind regards,
Founder and Executive Director, Canines-N-Kids Foundation www.caninesnkids.org
CADTH Lecture The Canadian Partnership for Tomorrow Project | Conférences de l’ACMTS Le Projet de partenariat canadien Espoir pour demain [register for the 16-Jan-2020, livestream]
The Canadian Partnership for Tomorrow Project: Canada’s Population Health Cohort
Speaker: Dr. Philip Awadalla, PhD, National Scientific Director for the CPTP, Director of Computational Biology, and the Executive Scientific Director of the Ontario Health Study at the Ontario Institute for Cancer Research, and Professor of Population and Medical Genomics at the University of Toronto.
The Canadian Partnership for Tomorrow Project (CPTP) is Canada’s largest population cohort that allows researchers to explore how genetics, environment, lifestyle, and behaviour interact and contribute to the development of cancer and other chronic diseases. The national cohort brings together six regional cohorts: BC Generations Project, Alberta’s Tomorrow Project, the Manitoba Tomorrow Project, Ontario Health Study, CARTaGENE, and the Atlantic Partnership for Tomorrow’s Health. These cohorts have cumulatively enrolled more than 320,000 Canadians who are older than 30. Baseline data has been harmonized across the country, creating a pan-Canadian resource of more than 1,600 measures of participant health and lifestyle factors, including, but not limited to: personal and family disease histories, medication use, sex and reproductive health, diet and nutrition, sun exposure, and alcohol and tobacco use. More than 150,000 participants have provided biological samples, measures of glycated hemoglobin, complete blood counts, and physical measurements (e.g., anthropometrics, blood pressure, and body fat percentage). A significant benefit of CPTP is that all participants have provided consent to link their information to regional administrative health databases. This unique feature enables the longitudinal analyses of changes in clinical outcomes carried out in parallel with the analysis of biologics and deeply characterized health and lifestyle information. Alongside a wealth of cardiometabolic phenotypes, CPTP is well positioned to support studies focused on how genetics and the environment interact to drive cancer, cardiovascular disease, diabetes onset, and other outcomes in the Canadian context.
Date: Thursday, January 16, 2020, in person or via live stream
Time: 1:30 p.m. to 2:45 p.m. EST
Location: Dow’s Lake Court Conference Centre, 865 Carling Avenue, Ottawa, Ontario
Live stream: Details on registration
There is no fee to participate, but you must register by Wednesday January 15, 2020, to attend or livestream the event.
Feel free to distribute this invitation within your networks. We sincerely hope you and your colleagues can join us. If you have any questions about the lecture or how to register, please contact us at email@example.com.
Le Projet de partenariat Canadien Espoir pour demain : la santé de la population au Canada
Conférencière : Le Dr Philip Awadalla est le directeur scientifique national du Projet de partenariat canadien Espoir pour demain, le directeur de la bio-informatique et le directeur général scientifique de l’Étude sur la santé Ontario à l’Institut ontarien de recherche sur le cancer. De plus, il enseigne la génomique des populations et la génomique médicale à l’Université de Toronto et il dirige le Centre canadien d’intégration des données de Génome Canada. Il est titulaire d’un doctorat en génétique des populations et en génétique statistique de l’Université d’Édimbourg. Il poursuit des études postdoctorales grâce à des bourses d’études (NSERC, Killam, Wellcome Trust), puis il occupe un poste de professeur aux universités de la Caroline du Nord et de Montréal. Pendant un temps, il est le directeur scientifique de CARTaGENE et fait partie du groupe d’analyse du projet 1 000 Génomes et du Pan-Cancer Analysis of Whole Genomes. Ses principaux projets sont axés sur la génomique du vieillissement, les maladies hématologiques et le cancer. D’autres portent sur l’estimation des taux de mutation et de recombinaison, la modélisation et la génétique, et les risques environnementaux de maladies infectieuses en Afrique.
Le Projet de partenariat canadien Espoir pour demain (PPCED) représente la plus vaste plateforme de recherche sur la santé de la population au Canada; dans le cadre de ce projet, des chercheurs étudient l’influence et l’interaction de facteurs génétiques et environnementaux, du mode de vie et du comportement dans l’apparition du cancer et d’autres maladies chroniques. D’importance cruciale, le PPCED permettra de mieux comprendre l’interaction entre des facteurs individuels comme le style de vie, le comportement et la génétique et l’environnement, et leur influence dans l’apparition du cancer et d’autres maladies. La cohorte nationale regroupe six cohortes régionales : le projet BC Generations, le projet Tomorrow de l’Alberta, le projet Tomorrow du Manitoba, l’Étude sur la santé Ontario, le projet CARTaGENE et le projet LA VOIE Atlantique; elle compte plus de 320 000 Canadiennes et Canadiens de plus de 30 ans. Les données de base recueillies au pays ont été harmonisées et elles forment une ressource pancanadienne portant sur plus de 1 600 paramètres mesurés sur la santé et le mode de vie, dont les antécédents médicaux personnels et familiaux, les médicaments utilisés, le sexe et la santé reproductive, le régime alimentaire et la nutrition, l’exposition au soleil, la consommation d’alcool et le tabagisme. Plus de 150 000 participants ont offert des échantillons biologiques, des mesures du taux d’hémoglobine glyquée, des hémogrammes et des mesures physiques (p. ex., caractéristiques anthropométriques, pression artérielle, pourcentage de gras corporel). L’une des retombées importantes du projet est que tous les participants ont consenti à ce que leurs renseignements personnels soient versés dans des bases de données administratives régionales du secteur de la santé. Ainsi, il est possible d’analyser dans une perspective longitudinale l’évolution des résultats cliniques en parallèle avec l’analyse des échantillons biologiques et de l’information individuelle étoffée sur la santé et le mode de vie. Corpus d’une vaste gamme de phénotypes cardiométaboliques, le PPCED constitue également une mine de renseignements permettant l’étude de l’interaction entre les facteurs génétiques et environnementaux dans l’apparition du cancer, des maladies cardiovasculaires, du diabète et d’autres problèmes de santé au Canada.
Date : Jeudi 16 janvier 2020
Heure : 13 h 30 à 14 h 45
Lieu : Salle du conseil, Dow’s Lake Court, ou en diffusion continue en direct
La conférence est offerte gratuitement, mais il faut s’y inscrire au plus tard mercredi 16 janvier 2020.
Inscrivez-vous dès maintenant: https://cadth.ca/fr/evenements/le-projet-de-partenariat-canadien-espoir-pour-demain-la-sante-de-la-population-au-canada
N’hésitez pas à partager cette invitation au sein de votre réseau. Nous espérons sincèrement que vous-même et certains de vos collègues pourrez vous joindre à nous lors de cette conférence. Si vous avez des questions à ce sujet ou encore pour savoir comment vous inscrire, n’hésitez pas à nous contacter à firstname.lastname@example.org.
C17 Council Call for Nominations for Co-Chair, C17 Human Resources Committee (MD) – Nominations accepted until 26 January 2020
The C17 Council has the following positions open for consideration:
Co-Chair, C17 Human Resources Committee (MD)
The C17 Council is searching for a Co-Chair for the C17 Human Resources committee. The C17 Human Resources committee is responsible for several initiatives including the support and encouragement of health professional “communities of practice”, workforce initiatives and surveys, and other topics that may be identified by the pediatric hematology/oncology profession.
The Co-Chair will work closely with the Affiliated Health Professional Co-Chair and be co-responsible for budgets, work and decisions of the committee, attendance on Council teleconferences and meetings. The Co-Chair, C17 Human Resources committee will serve a term of 3 years, renewable once. (After two terms, a new election will be called, but this does not exclude any incumbent from standing for additional terms).
Term commences June 2020.
Requirements: MD interested in working with the C17 Council
Expertise and experience in this area an asset but not required.
Nominations may be submitted by an individual interested in the position or a member of C17 to Dr. Conrad Fernandez, Chair of the C17 Nomination Committee and Kathy Brodeur-Robb, Executive Director, C17 Council, by email at Conrad.email@example.com and firstname.lastname@example.org.
The nominee must indicate that they accept the nomination, provide a brief description of their qualifications, vision and goals for the position, and provide a copy of their CV. Nominations will be accepted until the deadline listed above. The position will be voted on by the C17 Council.
Copied from December 2019 email GPFC update.
Since this fall, two new pediatric formulations identified as a priority by the GPFC, are now available to treat Canadian children: amlodipine oral solution and levetiracetam for injection. The announcement regarding levetiracetam will be sent by the GPFC in January.
The GPFC is also exploring collaborating with pharmaceutical companies to facilitate the approval and marketing of three other pediatric formulations.
Last summer, two position papers, endorsed by 17 organizations and written jointly with the Canadian Paediatric Society, on drugs for pediatric use have been published:
- Improving Pediatric Drugs: A Prescription for Canadian Children and Youth
- Pharmacare in Canada: A Pediatric Perspective
Recently, the Canadian Journal of Hospital Pharmacy agreed to publish an article written by the GPFC which reports on the delay in offering pediatric formulations adapted to Canadian children.
As part of its work to modernize the regulatory system, Health Canada is now putting more emphasis to pediatrics. Thus, three policies reviewed during the year include specific information on how pediatric drug submissions will be treated.
In early December, Dr. Catherine Litalien and Andrea Gilpin chaired two discussion sessions at the Children’s Health Canada Annual Conference in Ottawa.
On December 10, 2019, Andrea Gilpin, along with Dr. Robert Connelly, President of the Pediatric Chairs of Canada, were interviewed on CBC for the “Ottawa Morning” show with Robyn Bresnahan on the topic: “Drugs prescribe to children may not always be effective or safe as they should be”. Click here to listen the interview segment.
We would like to thank our partners and the pediatric community. We will continue to work together on important projects which aim at improving access to medicines for Canadian children.
For any inquiry, write to email@example.com
February 14, 2020 – (french only) Centenaire de la Faculté de pharmacie, les grandes conférences: Médicament et pédiatrie: Besoins non comblés
JOB POSTING: Locum Position, Pediatric Hematology/Oncology Dalhousie University/IWK Health Centre, Halifax, Nova Scotia
The Division of Pediatric Hematology/Oncology, Department of Pediatrics, Dalhousie University’s Faculty of Medicine and the IWK Health Centre in Halifax, Nova Scotia is seeking a locum tenens for all or part of a block up to 6 months between 1 January 2020 and 20 July 2020.
The IWK Health Centre www.iwk.nshealth.ca is an academic tertiary care pediatric and maternal care hospital and serves as the pediatric referral centre for the Maritime Provinces. The primary role of the locum will be in clinical with duties in pediatric hematology and oncology. Teaching would be a minor component of the role primarily focused on trainees rotating through the service. There are no expectations for research or administrative responsibilities.
The successful physician will join a team of five Pediatric Hematology/Oncology specialists. The service is supported by excellent hemato-and anatomic pathology laboratories and is a member of the Children’s Oncology Group. We work in conjunction with an excellent interdisciplinary team, sharing care with community pediatric teams, to serve approximately 55 new oncology and 80-100 new hematology patients diagnosed each year from across the Maritime Provinces.
Applicants must have a fellowship in Pediatrics from the Royal College of Physicians and Surgeons of Canada, or equivalent. They must also have completed, or be eligible for, the College’s examination for a Certificate in Special Competence in Pediatric Hematology Oncology. Eligibility for medical licensure in the Province of Nova Scotia is required.
A covering letter and curriculum vitae, along with the names of three referees (2 academic), should be directed to:
Conrad Fernandez MD, FRCPC
Professor, Departments of Pediatrics and Bioethics
Head, Division of Pediatric Hematology/Oncology
Dalhousie University and the IWK Health Centre
5850 University Avenue
Halifax, NS, B3K 6R8
With a copy to Administrative Assistant to Dr Fernandez: Mansurah Aziz Mansurah.firstname.lastname@example.org
Dalhousie University is committed to fostering a collegial culture grounded in diversity and inclusiveness. The university encourages applications from Aboriginal people, persons with a disability, racially visible persons, women, persons of minority sexual orientations and gender identities, and all candidates who would contribute to the diversity of our community. All qualified candidates are encouraged to apply; however, Canadians and permanent residents will be given priority.
JOB POSTING: Clinical Research Services Assistant Manager for Cell Therapeutics and Transplantation (closes 12-Jan-2020)
Full time position titled “Clinical Research Services Assistant Manager” and will be closing January 12/2020. Please see the full job description and qualification at : www.staffcareers.ubc.ca/36230.
Questions can be directed to Jessica Davis at email@example.com
This position is responsible for the start-up and initiation of clinical trials conducted by the Michael Cuccione Childhood Cancer Research Program (MC3RP) within the Children’s and Women’s Health Centre of BC’s Division of Hematology/Oncology/Bone Marrow Transplant (Hem/Onc/BMT) and the BC Children’s Hospital Research Institute.
The primary function of the position is to perform research activities for the cellular therapeutics and Blood and Marrow Transplantation (BMT) programs with planned expansion into other research programs within the MC3RP. Specifically, they will be a primary liaison for CureWorks, PedCITN, CBMTG, PBMTC, as well as all related industry sponsored studies associated with the program.
The incumbent will perform research related activities encompassing UBC.CW Research Ethics Board (REB) applications, contracts, finance, regulatory, departmental approvals and initiation of primarily but not limited to cellular therapy and bone marrow transplant clinical research studies with planned expansion into other programs of research within the Childhood Cancer and Blood Research Program.
The incumbent is required to conduct all research activities in an ethical manner, suited to the regulations of the University of British Columbia and to the professional organizations governing his or herself and those governing the activities of the institution and all other investigators. Any procedures undertaken as part of the trial start-up must follow applicable regulatory guidelines. Strict confidentiality of all study matters must be adhered to. The incumbent’s research activities are accountable to the study Principal Investigator, the Director of the MC3RP, and the candidate’s governing professional organization.